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Summary Tumour growth is angiogenesis dependent. Some authors suggest a prognostic role of microvessel count in colorectal cancer. We
tested the role of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in the switch to the angiogenic
phenotype in 35 patients with colorectal cancer at different stages of disease. We evaluated the two angiogenic factors, by enzyme-linked
immunosorbent assay (ELISA), in tumour, peritumoral mucosa, pathological mesenteric and peripheral blood. We used ten endoscopic
intestinal biopsies and ten peripheral blood samples from healthy subjects as control. bFGF was significantly lower in tumour tissues and in
peritumoral mucosas than in healthy mucosas, whereas VEGF was up-regulated in tumours but not in peritumoral mucosa. Both angiogenic
factors were greatly increased in mesenteric blood. VEGF tumour and serum levels were significantly correlated with the stage of disease.
bFGF tumour and serum concentration were not correlated with the stage of disease. The high levels of bFGF in mesenteric blood suggest
that this growth factor might be abnormally released from tumour tissue and peritumoral mucosa and could function as an early effector in the
switch to the angiogenic phenotype. In contrast, VEGF, whose levels show a significant correlation with the stage of disease, could act in a
following step, supporting tumour progression.
Keywords: basic fibroblast growth factor; vascular endothelial growth factor; colorectal cancer; angiogenic factor; enzyme-linked
immunosorbent assay
Angiogenesis consists of the sprouting of capillaries from pre-
existing vessels. This physiological process is fundamental in
reproduction, development and wound repair (Folkman, 1995).
Angiogenesis is deregulated in several pathological conditions.
Growth oftumour mass is made possible not only because ofperfu-
sion ofblood through the tumour, but also because ofthe paracrine
stimulation oftumour cells by numerous growth factors and matrix
proteins that are produced by the new capillary endothelium. It has
been suggested that the switch to the angiogenic phenotype
depends on a net balance between positive and negative angiogenic
factors released by the tumour (Folkman, 1995).
Weidner et al (1991) demonstrated a statistically significant
correlation between the incidence of metastases and intratumoral
microvessel density (IMD) in invasive breast carcinomas. This
finding was confirmed in several studies in early-stage breast
cancer (Weidner et al, 1992), melanoma (Graham et al, 1994),
cervical (Smith-McCune and Weidner, 1994) and prostate carci-
noma (Weidner et al, 1993).
Vermeulen et al (1995) described increased IMD in areas of
invasive colon cancer compared with IMD in areas of in situ
growth without any prognostic evaluation. Moreover, IMD was
found to be greater in metastatic tumour than in non-metastatic
tumour (Takahashi et al, 1995). The prognostic role ofmicrovessel
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count in colorectal cancer was investigated by several authors with
controversial results. IMD was significantly correlated with the
presence ofliver metastasis (Tomisaki et al, 1996), haematogenous
metastasis (Tanigawa et al, 1997), relapse and overall survival
(Frank et al, 1995; Takahashi et al, 1997). Opposite results are
reported by Bossi et al (1995), who did not find any association
among IMD, metastasis, stage of disease and patient survival, and
by Lindmark et al (1996) who demonstrated a significant correla-
tion between increased IMD and better survival. All these different
data could be due to different methods used to process tissues and
to quantify microvessels.
Basic fibroblast growth factor (bFGF) has a potent mitogenic
activity for a wide variety of mesoderm-neuroectoderm-derived
cells. This peptide stimulates vascular endothelial cell prolifera-
tion and virtually all these cells either produce or have receptors
for bFGF. It has been demonstrated that bFGF is involved in the
neoplastic angiogenesis of several types of tumours (melanomas,
glioblastoma, Kaposi sarcoma, pancreas, renal, breast and lung
tumours) (Basilico and Moscatelli, 1992).
Recently, considerable interest has developed in the possible
participation of the endothelial mitogen vascular endothelial
growth factor (VEGF) in malignant tumour growth. VEGF is
mitogenic for a variety oflarge- and small-vessel endothelial cells,
induces the production of tissue factors, collagenase, plasminogen
activators and their inhibitors, and stimulates hexose transport in
these cells as well. VEGF is also known as 'vascular permeability
factor' by virtue of its permeability enhancing effects. VEGF
expression has been demonstrated in several human cancer cell
lines in vitro and in surgically resected tumours of the gastro-
intestinal tract, ovary, brain, breast and kidney (Thomas, 1996).
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Table 1 Summary of analysed samples
Tissues analysed No. of samples
No. of patients 35
bFGF dosage
Tumour 32
Peritumoral mucosa 1 cm 10
Peritumoral mucosa 5 cm 32
Peritumoral mucosa 10 cm 10
Post-operative mucosa 7
Healthy mucosa 10
Pathological mesenteric blood 20
Pathological peripheral blood 21
Healthy peripheral blood 10
VEGF dosage
Tumour 20
Peritumoral mucosa 20
Healthy mucosa 10
Pathological mesenteric blood 20
Pathological peripheral blood 20
Healthy peripheral blood 10
VEGF and bFGF are both secreted, although some authors have
demonstrated that bFGF is secreted by an alternative secretion
pathway (Bussolino et al, 1996). Moreover, recent studies demon-
strated that VEGF receptor is not specific for endothelial cells, as
previously reported for bFGF receptor (Brown et al, 1997; Ergun
et al, 1997).
In an effort to better understand the role of bFGF and VEGF in
colorectal cancer, we measured by enzyme-linked immunosorbent
assay (ELISA) the levels of these angiogenic factors in a series of
human colorectal cancer and in blood samples from peripheral and
mesenteric veins.
PATIENTS AND METHODS
Patients
Between February and December 1996, specimens were obtained
from 35 patients with colorectal adenocarcinoma. The group was
composed of20 men and 15 women. The mean age was 62.7 years
(range 32-82). Primitive tumour was present in the right colon in
12 cases, in the transverse colon in two cases, in the left colon in
five cases, in the sigmoid colon in 11 cases and in the rectum in
five cases. All cases were staged according to Dukes' (modified
according to Astler-Coller) and TNM classifications; Dukes: B,,
three cases; B2, ten cases; C,, four cases; C2, ten cases; D, eight
cases; TNM: T2, eight cases; T3, 24 cases; T4, three cases; node
negative, 17 cases; node positive, 18 cases; metastasis negative, 27
cases; metastasis positive, eight cases (De Vita et al, 1997).
Histological grading was G2 in 19 cases and G3 in 16 cases.
Thirty-two specimens of tumours and healthy mucosa at 5 cm
from the tumour were collected; moreover, in ten patients, speci-
mens ofhealthy mucosa at I and 10 cm from the tumour were also
collected. Surgical procedures allowed us to collect blood samples
from mesenteric vein in only 20 patients; 21 blood specimens from
the brachial vein (peripheral blood) were collected in the same
group of patients. All these samples were intraoperative speci-
mens, obtained during the surgical removal of the tumour. Seven
patients were submitted to an endoscopic examination with a
biopsy ofcolon mucosa 6 months after surgery. A control group of
informed and voluntary subjects was selected in the same range of
age and sex as the pathological one. Among these subjects we
collected ten endoscopic specimens of bowel mucosa and ten
peripheral blood samples.
The tissues were divided in 125-mm3 pieces, immediately
frozen in liquid nitrogen and stored at-80°. Samples were thawed
only once and were analysed 15-30 days after collection; one
piece was used for histology, one each for bFGF and VEGF
ELISAs. Histology was confirmed in all cases. Serum was
obtained from blood specimens and stored at-80°.
Samples
Tissue specimens were homogenized in potassium phosphate
buffer (200 mg wet weight ml-') as described previously in
Landriscina et al (1996), protein concentration was determined
spectrophotometrically with a Biorad kit according to the manu-
facturer's procedures. Blood sera were analysed directly.
Table 2 Mean bFGF and VEGF content in tumour, mucosa and blood
Tissue bFGF levels VEGF levels
No. of patients bFGF (pg mg-' proteins)a No. of patients VEGF (ng mg-1 proteins)b
Tumour 32 1066.4 + 514 20 14.3 7
Peritumoral mucosa (5 cm) 32 1954.2 ± 692 20 5.3 + 2
Healthy mucosa 10 3694.0 + 1501 10 4.7+ 2
Tissue bFGF levels VEGF levels
No. of patients bFGF (pg ml-' serum)c No. of patients VEGF (ng ml-' serum)d
Pathological mesenteric blood 20 58.3 + 37 20 15.0 +8
Pathological peripheral blood 21 14.3 + 12 20 11.2 ± 4
Healthy peripheral blood 10 6.1 + 3 10 11.8 + 5
aTumour vs peritumoral mucosa P < 0.0000003, peritumoral vs. healthy mucosa P < 0.000009, tumour vs healthy mucosa P< 0.0000000002. bTumour vs
peritumoral mucosa P < 0.000003, peritumoral vs healthy mucosa NS, tumour vs healthy mucosa P < 0.0002. cMesenteric vs peripheral blood P< 0.000009,
peripheral vs healthy blood P < 0.04. dMesenteric vs peripheral blood NS, peripheral vs healthy blood NS.
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Figure 1 bFGF levels in healthy and pathological tissues (A and B) and VEGF levels in healthy and pathological tissues (C and D)
bFGF dosage
bFGF ELISA kit was purchased from Wako Chemical and the
procedures included were followed. The kit used three monoclonal
antibodies: clones no. 52 and 98 with similar antigenic recognition
and clone no. 3H3 HRP-conjugated FAB' prepared from a mono-
clonal antibody having another epitope recognition. bFGF was
quantified by using a standard curve made by human bFGF
ranging from 3 pg ml to 500 pg ml. The chromogenic reaction
was read at the absorbance of490 nm (Watanabe et al, 1991).
VEGF dosage
A competitive enzyme immunoassay that measures natural and
recombinant forms of VEGF was purchased from Chemicon
International and the procedures included were followed. The kit
used a polyclonal anti-VEGF antibody. VEGF concentration was
dosed according to a standard curve ranging from 0.19 to
800 ng ml-'. The chromogenic reaction was read at 490 nm.
Statistical analyses
Differences in mean content of bFGF and VEGF among tumour,
mucosa and blood samples were analysed by Student's t-test. The
correlation between bFGF, VEGF and the stage of disease was
examined by the Kendall Tau test. For all statistical analyses, the
level of significance was set at P < 0.05. Statworks statistical soft-
ware (Statistic for Windows, Statsoft, 1993) was used for all
analyses.
RESULTS
bFGF levels
We evaluated the bFGF content in 32 specimens of colorectal
cancer and in 32 specimens of histologically not infiltrated peri-
tumoral mucosa (5 cm from the tumour); we also tested 20
samples of mesenteric blood and 21 samples of peripheral blood.
We used ten endoscopic intestinal biopsies and ten samples of
peripheral blood from healthy subjects as controls (Table 1). The
analytical patients' data are reported in Table 2 and Figure 1 A
and B. bFGF mean content in healthy normal mucosa was
3694.0 ± 1501 pg mg-' of total proteins, in tumour tissues it was
1066.4 ± 514 pg mg-' of total proteins and in peritumoral mucosa
it was 1954.2 ± 692 pg mg-' oftotal proteins. t-test demonstrated a
highly significant difference between healthy mucosa and tumour
tissue (P < 0.0000000002), between peritumoral mucosa and
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Table 3 Mean bFGF content in mucosa at different distances from tumour
and in post-operative mucosa (in 10 of 32 patients)
Tissue No. of cases bFGF (pg mg-' of total
proteins)
Tumour 10 1468.7 + 447
Peritumoral mucosa (1 cm) 10 1748.5 + 525
Peritumoral mucosa 11 (5 cm) 10 2449.8 + 417
Peritumoral mucosa III (10 cm) 10 2509.8 ± 604
lntraoperative mucosa 7 1679.0 + 903
Postoperative mucosa (6 months) 7 2294.8 + 612
Table 4 Correlation between VEGF levels and stage of disease
P-values (determined by the Kendal Tau test)
Tumour Mesenteric blood Peripheral blood
TNM 0.02 0.007 0.002
T _,a 0.009 0.002 0.002
N-/N+a NS NS NS
M-/M+a 0.004 NS 0.01
Dukes 0.02 0.005 0.03
aT, primitive tumour; N, node metastasis; M, distant metastasis.
tumour tissue (P < 0.0000003) and between peritumoral mucosa
and healthy mucosa (P < 0.000009).
Mean bFGF level in healthy peripheral blood was 6.1 ± 3 pg ml-',
in pathological peripheral blood it was 14.3 ± 12 pg ml' and in
pathological mesenteric blood it was 58.3 ± 37 pg ml-' (Table 2). The
difference between pathological mesenteric and pathological periph-
eral blood was highly significant (P < 0.000009). The difference
between pathological and healthy peripheral blood was also signifi-
cant, although to a lesser extent (P < 0.04).
In order to explore the role oftumour tissue on bFGF content of
peritumoral mucosa, we dosed bFGF at different distances from
the primitive tumour and in post-operative endoscopic biopsies
from patients who had previously undergone to radical surgery for
adenocarcinoma (Table 3). We observed that the bFGF content in
mucosa close to the tumour was nearly the same as tumour itself,
as expected (1748.5 ± 525 vs 1468.7 ± 447; P < 0.3); otherwise
bFGF content in mucosa at 5 cm and 10 cm from the tumour was
significantly higher than the tumour itself (2449.8 ± 417 and
2509.8 + 604; P < 0.00008 and P < 0.0004 respectively). bFGF
content in mucosa at 10 cm from the tumour was still significantly
lower than the healthy control (2509.8 ± 604 vs 3694.0 ± 1501;
P < 0.04). Seven patients were submitted to endoscopy 6 months
after radical surgery: mean bFGF content ofmucosa was higher in
post-operative specimens than in intraoperative ones, but this
difference was not statistically significant (2294.8 ± 612 vs
1679.0 ± 903; P < 0.2). The bFGF content of endoscopic post-
operative mucosa was found to be still lower than the mucosa of
healthy patients (P < 0.04).
VEGF levels
VEGF levels were determined in 20 adenocarcinomas of the
colon-rectum, in 20 peritumoral mucosas (5 cm from the tumour)
and in ten endoscopic biopsies from healthy patients (Table 1).
Table 2 and Figure 1 C-D report analytical data. Significantly
higher mean VEGF levels were observed in tumour tissue
(14.3 ± 7 ng mg-' of total proteins) than in peritumoral mucosa
(5.3 ± 2; P < 0.000003); the difference in VEGF content between
tumour and healthy mucosa was also statistically significant
(4.7 ± 2; P < 0.0002). Apart from bFGF, peritumoral mucosa and
healthy mucosa have the same VEGF content (P < 0.5). In the same
group of patients the mean VEGF levels in mesenteric and periph-
eral blood were 15.0 ± 8 and 11.2 ±4 ng ml-' respectively. Normal
peripheral blood mean VEGF content was 11.8 ± 5 ng ml-' (Table
2). The difference between pathological VEGF mesenteric and
peripheral levels was not statistically significant, nor was the differ-
ence between normal and pathological peripheral VEGF content.
Correlation between VEGF and bFGF levels and stage
of disease
The Kendall Tau test demonstrated a statistically significant corre-
lation between VEGF levels and stage of disease (Table 4). We
observed a significant correlation between VEGF content in
tumour, mesenteric and peripheral blood and Dukes' stage of
disease (P < 0.02; P < 0.005; P < 0.03). same correlation was also
significant with TNM stage (P < 0.02, P < 0.007, P < 0.002). The
correlation was more significant when we compared VEGF levels
in tumour, mesenteric and peripheral blood and T evaluated
according to the TNM classification (P < 0.009; P < 0.002; P <
0.002). Tumour and peripheral VEGF levels were also correlated
with the presence of distant metastases (P < 0.004; P < 0.01). We
did not observe any significant correlation between VEGF content
and node metastases according to TNM.
We did not find any significant correlation between tissue or
serum bFGF levels and Dukes' or TNM stages, grading as well as
node or distant metastases. Moreover, the Kendall Tau test did not
demonstrate any significant correlation between bFGF and VEGF
levels in tumours, mesenteric and peripheral blood.
DISCUSSION
The aim of the present study was to investigate the possible
regulatory activity of bFGF- and VEGF-driven angiogenesis in
colorectal cancer. The experimental model includes colorectal
tumours at different stages of disease, with or without node and
distant metastases. The content of the angiogenic factors was
comparatively evaluated in tumours, peritumoral mucosa that was
not infiltrated and mucosa from healthy subjects. In a subgroup of
patients we also obtained intraoperative blood samples from the
mesenteric vein, which drains blood from the bowel and from the
brachial vein (peripheral blood).
We observed that the bFGF content was significantly lower in
tumour tissue than in peritumoral mucosa and that the bFGF levels
in peritumoral mucosa were unexpectedly lower than in healthy
mucosa. To establish that the difference between peritumoral and
healthy mucosa did not depend on the method of sampling (intra-
operative vs endoscopic), we also measured bFGF in preoperative
endoscopic biopsies of peritumoral mucosa in three patients,
obtaining values similar to those observed in intraoperative peri-
tumoral mucosa (data not shown). In spite of the low bFGF levels
in tumour tissue, its content in mesenteric blood was higher than
in the peripheral blood of the same patients. Peripheral blood
bFGF levels were still higher than those in healthy subjects.
Even though bFGF lacks a leader sequence for secretion, several
reports suggest that bFGF is secreted from bFGF-producing cells
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by an alternative secretion pathway (Bussolino et al, 1996) and that
it accumulates in the extracellular matrix (ECM), where it can be
released by ECM-degrading enzymes (Vlodavski et al, 1991). In
order to explore the possibility that tumour could influence the
content of bFGF in tumour itself and in peritumoral mucosa, we
measured bFGF levels in the mucosa at different distances from the
tumour. We observed that bFGF content in mucosa 5 and 10 cm
from the tumour was higher than that ofmucosa 1 cm from tumour.
Although these data do not investigate the mechanisms of the
possible release of bFGF from tumour cells and peritumoral
mucosa, they suggest that the presence of tumour could influence
bFGF release. Kandel et al (1991) described a similar observation
in the multistep development offibrosarcoma in a transgenic mouse
model. They found a change in the localization of bFGF from its
normal cell-associated form in the normal dermal fibroblast and
mild fibromatosis to extracellular release in aggressive fibromatosis
and fibrosarcoma.
These data do not exclude the possibility that the decrease in
bFGF might represent an early onset sign of transformation, apart
from the presence of the tumour. In support of this possibility,
bFGF content in endoscopic biopsies of intestinal mucosa,
obtained from patients previously submitted to radical surgery for
colorectal cancer, was still lower than in healthy mucosa.
Experimental data demonstrated that the expression of VEGF
was up-regulated by an abnormality in p53, which is one of the
most commonly mutated tumour-suppressor genes in colorectal
cancer (Kieser et al, 1994; Mukhopadhyay et al, 1995; Kang et al,
1997). Takahashi et al (1995) demonstrated that the expression of
VEGF and its receptors KDR was higher in metastatic than in non-
metastatic neoplasms and that it was directly correlated with the
extent of neovascularization and the degree of proliferation.
Moreover, VEGF mRNA was found to be ubiquitously expressed
in human liver metastases from primary colon or rectal cancers
(Warren et al, 1995). Recently Dirix et al (1996) dosed bFGF and
VEGF in sera from patients bearing advanced colorectal cancer.
They observed that the levels of these angiogenic factors are
predictive of the progression of disease. In agreement with these
results, Takahashi et al (1997) demonstrated, in patients with node-
negative colon cancer, that VEGF expression in tumours, as well
as IMD, are significantly related to the recurrence.
We measured VEGF in 20 patients and we found that it was
increased in tumour tissue in comparison with peritumoral mucosa
as well as with healthy mucosa. Moreover, VEGF levels in mesen-
teric blood were higher than in peripheral pathological and healthy
blood. Statistical analyses demonstrated that VEGF levels in
tumour, mesenteric and peripheral blood were significantly corre-
lated with tumour stage according to Dukes' and TNM classifica-
tions. We have also compared VEGF levels with the different
parameters of TNM. We observed a strong correlation between
VEGF and the extent of intestinal wall invasion and a less signifi-
cant correlation with distant metastases. On the other hand, we did
not find any correlation between VEGF levels and the presence of
node metastases. These observations suggest that node metastases
might not be dependent on VEGF-induced angiogenesis.
The different bFGF and VEGF content between pathological
peripheral and mesenteric blood could be due to the short half-life of
the two growth factors and to their deposition in solid organs such as
kidney, liver and spleen (Edelman et al, 1993; Folkman, 1995).
Folkman (1995) hypothesized that tumour cells, endothelial
cells or macrophages may secrete specific growth factors (tumour
angiogenesis factors) for the proliferation of endothelial cells,
C) Cancer Research Campaign 1998
which may stimulate the proliferation of new blood vessels in an
expanding tumour volume. The role of these angiogenic proteins
on the biological system ofcolorectal cancer is still not completely
understood.
Our data do not characterize the cells involved in the production
of bFGF and VEGF, but show that they are probably involved in
colorectal cancer angiogenesis with different mechanisms. The
lack ofany correlation between bFGF levels in tumour and mesen-
teric blood and the stage of disease could suggest that the release
of bFGF from tumour and peritumoral cells is an early but prob-
ably not specific event in the switch to the angiogenic phenotype
in colorectal cancer. The increased production ofVEGF according
to the stage and the depth of intestinal wall invasion suggests that
it could be involved in a later step of the angiogenesis process.
Their sequential secretion could represent one of the possible
sequences of events that contribute to neoplastic progression and
metastasis. This hypothesis might be in agreement with recent
studies that have demonstrated the possible synergistic effects of
VEGF and bFGF on the induction of angiogenesis either in vitro
(Goto et al, 1993) or in vivo (Asahara et al, 1996).
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